Select Publications
Conference Abstracts
, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017
, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0
, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1
Reports
, 2021, Progress towards hepatitis C elimination among Aboriginal and Torres Strait Islander people in Australia: monitoring and evaluation report, The Kirby Institute, UNSW Sydney, Sydney, Australia, https://kirby.unsw.edu.au/report/progress-towards-hepatitis-c-elimination-among-aboriginal-and-torres-strait-islander-people
, 2020, Human T-lymphotropic virus type 1: technical report, World Health Organization, Geneve, https://apps.who.int/iris/handle/10665/339773
Theses / Dissertations
, 2022, Hepatitis C elimination among people living with HIV, http://dx.doi.org/10.26190/unsworks/24455
Preprints
, 2025, Development of a machine learning model to predict short duration HCV treatment response, http://dx.doi.org/10.1101/2025.09.19.25336147
, 2023, A unique cytotoxic CD4+T cells signature defines critical COVID-19, http://dx.doi.org/10.1101/2023.02.17.23286059
, 2022, Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients, http://dx.doi.org/10.1101/2022.10.19.512954
, 2021, Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection, http://dx.doi.org/10.1101/2021.12.21.473774
, 2020, Long-term persistence of neutralizing memory B cells in SARS-CoV-2, http://dx.doi.org/10.21203/rs.3.rs-92527/v1
, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916
, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248
, Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2, http://dx.doi.org/10.2139/ssrn.3732365
, Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses, http://dx.doi.org/10.2139/ssrn.3920641
, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607